Skip to main content
Journal cover image

Dose intensive melphalan and cyclophosphamide with autologous hematopoietic stem cells for recurrent medulloblastoma or germinoma.

Publication ,  Journal Article
Kadota, RP; Mahoney, DH; Doyle, J; Duerst, R; Friedman, H; Holmes, E; Kun, L; Zhou, T; Pollack, IF
Published in: Pediatr Blood Cancer
November 2008

PURPOSE: To determine the response, toxicity, and survival for children with progressive or recurrent medulloblastoma and germinoma using a single myeloablative course of chemotherapy supported by autologous hematopoietic stem cells. PATIENTS AND METHODS: Subjects were in second remission or had minimal residual disease at the time of study entry. The conditioning regimen consisted of cyclophosphamide 6,000 mg/m(2) plus melphalan 180 mg/m(2). RESULTS: Twenty-nine evaluable pediatric patients were accrued. The most frequent major toxicities were myelosuppression, infections, and stomatitis, but no toxic deaths were recorded. Best responses were: CR = 6, CCR = 13, PR = 6, SD = 2, and PD = 2. There were 6 medulloblastoma and 3 germinoma survivors with a median follow-up of 7.5 years (range = 2.8-10). Two germinoma survivors received radiotherapy after autografting for presumptive progressive disease. CONCLUSION: Myeloablative chemotherapy consisting of cyclophosphamide and melphalan was tolerable in the relapsed brain tumor setting with 19/29 cases achieving CR or CCR status and 9/29 becoming long-term survivors.

Duke Scholars

Published In

Pediatr Blood Cancer

DOI

EISSN

1545-5017

Publication Date

November 2008

Volume

51

Issue

5

Start / End Page

675 / 678

Location

United States

Related Subject Headings

  • Transplantation, Autologous
  • Oncology & Carcinogenesis
  • Neoplasm Recurrence, Local
  • Melphalan
  • Medulloblastoma
  • Kaplan-Meier Estimate
  • Humans
  • Hematopoietic Stem Cell Transplantation
  • Germinoma
  • Cyclophosphamide
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kadota, R. P., Mahoney, D. H., Doyle, J., Duerst, R., Friedman, H., Holmes, E., … Pollack, I. F. (2008). Dose intensive melphalan and cyclophosphamide with autologous hematopoietic stem cells for recurrent medulloblastoma or germinoma. Pediatr Blood Cancer, 51(5), 675–678. https://doi.org/10.1002/pbc.21655
Kadota, Richard P., Donald H. Mahoney, John Doyle, Reggie Duerst, Henry Friedman, Emi Holmes, Larry Kun, Tianni Zhou, and Ian F. Pollack. “Dose intensive melphalan and cyclophosphamide with autologous hematopoietic stem cells for recurrent medulloblastoma or germinoma.Pediatr Blood Cancer 51, no. 5 (November 2008): 675–78. https://doi.org/10.1002/pbc.21655.
Kadota RP, Mahoney DH, Doyle J, Duerst R, Friedman H, Holmes E, et al. Dose intensive melphalan and cyclophosphamide with autologous hematopoietic stem cells for recurrent medulloblastoma or germinoma. Pediatr Blood Cancer. 2008 Nov;51(5):675–8.
Kadota, Richard P., et al. “Dose intensive melphalan and cyclophosphamide with autologous hematopoietic stem cells for recurrent medulloblastoma or germinoma.Pediatr Blood Cancer, vol. 51, no. 5, Nov. 2008, pp. 675–78. Pubmed, doi:10.1002/pbc.21655.
Kadota RP, Mahoney DH, Doyle J, Duerst R, Friedman H, Holmes E, Kun L, Zhou T, Pollack IF. Dose intensive melphalan and cyclophosphamide with autologous hematopoietic stem cells for recurrent medulloblastoma or germinoma. Pediatr Blood Cancer. 2008 Nov;51(5):675–678.
Journal cover image

Published In

Pediatr Blood Cancer

DOI

EISSN

1545-5017

Publication Date

November 2008

Volume

51

Issue

5

Start / End Page

675 / 678

Location

United States

Related Subject Headings

  • Transplantation, Autologous
  • Oncology & Carcinogenesis
  • Neoplasm Recurrence, Local
  • Melphalan
  • Medulloblastoma
  • Kaplan-Meier Estimate
  • Humans
  • Hematopoietic Stem Cell Transplantation
  • Germinoma
  • Cyclophosphamide